In Brief: Li Medical Technologies
This article was originally published in The Gray Sheet
Executive SummaryLi Medical Technologies: Privately held fixation technology firm is developing a new minimally invasive "sutureless suspension approach to bladder neck suspension surgery" for treatment of female incontinence, states Scott Gillis, president, at the March 6 UBS Securities women's health conference in New York City. The Shelton, Connecticut-based firm, which has 12 employees and was founded in 1991, also is developing products for spinal fusion. Its current product, the UltraFix suture anchor, was launched in the U.S. in December 1995 and is used for bladder neck suspension and for sports medicine applications...
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.